Abstract. emodin has been demonstrated to inhibit the fibrotic process in chronic renal disease, but its mechanisms have yet to be fully elucidated. This study was carried out to investigate the effects of emodin on extracellular matrix (ecM) synthesis in TGF-β1-stimulated NRK-49F cells. NRK-49F cells stimulated with TGF-β1 were incubated with various concentrations of emodin. ECM proteins, including collagen type III and fibronectin, were detected using ELISA. ERK1/2, p38 and JNK phosphorylation were measured by Western blotting. p38, ERK1/2 and JNK were respectively inhibited with the specific inhibitors SB203580, PD98059 and SP600125. Emodin slightly inhibited the expression of fibronectin and collagen type III in NRK-49F cells without TGF-β1 treatment, and significantly suppressed fibronectin and collagen type III secretion in TGF-β1-stimulated NRK-49F cells. ERK1/2 and p38 specific inhibitors, but not JNK inhibitor, suppressed the TGF-β1-induced expression of fibronectin and collagen type III. Our previous study demonstrated that there was no crosstalk between ERK1/2, p38 and JNK signals in TGF-β1-stimulated NRK-49F cells. Here, we found that emodin inhibited the phosphorylation of ERK1/2 and p38 significantly, but did not suppress the phosphorylation of JNK. In summary, emodin suppresses fibronectin and collagen type III expression via the inhibition of ERK1/2 and p38 phosphorylation in TGF-β1-stimulated NRK-49F cells.
Introduction
Emodin, 3-methyl-1,6,8-carboxyl-anthraquinone, is an anthra quinone derivative isolated mainly from the Chinese herb Rheum palmatum. It has been demonstrated to inhibit the fibrosis process of various organs, including the liver, pancreas, peritoneum and kidney (1) (2) (3) . Emodin suppresses p38 phosphorylation to inhibit cell proliferation and fibronectin expression in mesangial cells cultured in high-glucose solution (4) . It also suppresses IL-1β-induced extracellular matrix (ECM) synthesis in mesangial cells (5) . However, its mechanism is not fully elucidated.
TGF-β1 is a cytokine that plays an essential role in renal fibrosis in various kidney diseases to promote renal failure. It induces the synthesis of ECM protein, including collagen type III and fibronectin. The most important downstream factors mediating the ECM synthesis of TGF-β1 are mitogen-activated protein kinase (MAPK) signals, including extracellular signal-regulated kinase (ERK), p38 MAP kinase and c-jun N-terminal kinase (JNK). ERK mediates TGF-β1-induced synthesis of plasminogen activator inhibitor type I (6), CTGF (7) and aldsterone-stimulated collagen synthesis (8) . ERK is also involved in the ECM synthesis in diabetic rats (9) . p38 mediates TGF-β1-stimulated ECM synthesis in mesangial cells (10) and proximal tubular cells (11). Angiotensin II promotes ECM synthesis by activating the ERK and p38 pathways (12) . ERK, p38 and JNK are also involved in the process of renal fibrosis in UUO rats (13) (14) (15) . The activation of ERK and p38 induces the synthesis of TGF-β1 to form a vicious cycle aggravating renal fibrosis (16) .
Renal fibroblasts differentiate into myofibroblasts under the persistent injury involved in the overproduction and deposition of the interstitial matrix in fibrotic kidneys. They also differentiate into myofibroblasts with the up-regulation of ECM production upon TGF-β1 stimulation. To date, there have been no reports concerning the effects of emodin on the MAPK pathways in renal interstitial fibroblasts.
In the present study, we investigated the effects of emodin on MAPK pathway to induce ECM synthesis in TGF-β1-stimulated NRK-49F cells, a cell line of renal interstitial fibroblasts. Determination of LDH release in NRK-49F cells. Confluent NRK-49F cells were cultured under control and experimental conditions in 96-well plates for 24 h. Supernatants were collected, centrifuged for 10 min at 2,000 x g, and assessed for LDH release using a commercially available kit according to the manufacturer's instructions. The cytotoxicity of the control and experimental samples was expressed as the percentage of LDH release compared to total intracellular LDH content.
Materials and methods

Materials
Enzyme-linked immunosorbent assay (ELISA).
Collagen type III and fibronectin accumulation in the supernatants was quantified using ELISA following the manufacturer's instructions. In brief, after a 24-h incubation with the compounds, the samples and standards were transferred to 96-well microplates pre-coated with specific collagen type III or fibronectin antibodies and incubated for 2 h. After the plates were washed and decanted, biotinylated rat fibronectin or collagen type III antibodies were added to each well, followed by incubation for 60 min. Then, streptavidin-peroxidase conjugate was added to each well and the plates were incubated for 30 min. Subsequently, chromogen substrate was added, the plates were incubated for 10 min, then the stop solution was added to each well. The absorbance was read at 450 nm in an ELISA reader. The values of each sample were normalized to the protein concentrations measured using the Bradford assay (BioRad, CA, USA).
Western blotting. Cells were washed three times with PBS, added to lysis buffer (Shengneng Biotech, Shanghai, China) and vortexed thoroughly. Protein concentrations were determined by the Bradford method. Then, 5X loading buffer was added to the protein and the mixture was boiled for 5 min. Protein from each sample (80 µg) was divided by SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). The membranes were blocked with 5% skimmed milk and then incubated in primary antibody overnight. The membranes were then washed with Tris-buffered saline, followed by incubation with horseradish peroxidase-conjugated second antibody for 2 h. Lastly, the membranes were incubated in Supersignal West Dura Extended Duration Substrate (Pierce, USA) and exposed to X-ray film.
Statistical analysis. Data were expressed as the mean ± SD and analyzed by one-way ANOVA with the LSD test for multiple comparisons. P-values <0.05 were considered significantly different.
Results
Cytotoxic effects of emodin by LDH analysis.
To determine the optimal concentration of emodin to be applied in NRK-49F cells, an LDH test of various concentrations of emodin (0-150 µg/ml) was performed. The LDH release increased to ~21% in 50 µg/ml emodin. Based on these findings, emodin concentration from 0 to 40 µg/ml were used to investigate the concentration-dependent effects of emodin on ECM synthesis and the activation of MAPK signals.
Emodin slightly inhibited the expression of collagen type III and fibronectin in NRK-49F cells without TGF-β1 stimulation.
The effects of emodin on the synthesis of collagen type III and fibronectin were investigated in NRK-49F cells using ELISA. Emodin slightly reduced fibronectin and collagen type III expression as compared to normal control cells (Fig. 2) .
Emodin significantly inhibited ECM synthesis in TGF-β1-stimulated NRK-49F cells.
The effects of emodin on the synthesis of collagen type III and fibronectin were then examined in TGF-β1-stimulated NRK-49F cells using ELISA. Emodin inhibited the synthesis of collagen type III in a dosedependent manner, and significantly suppressed fibronectin synthesis (Fig. 3) .
Effects of MAPK inhibition on ECM synthesis. Our previous study indicated that there is no crosstalk between ERK1/2, p38 and JNK in TGF-β1-stimulated NRK-49F cells (17) . Here, we blocked each of these three MAPK pathways using their specific inhibitor to investigate the role of MAPK in ECM synthesis. PD98059 and SB202190 significantly reduced fibronectin and collagen type III synthesis in TGF-β1-stimulated NRK-49F cells. SP600125 did not significantly suppress the secretion of fibronectin and collagen type III (Fig. 4) . 
Emodin inhibited the phosphorylation of ERK1/2 and p38.
Our previous study demonstrated that TGF-β1 activates ERK1/2, p38 and JNK in NRK-49F cells (17) . Here, the effects of emodin on the phosphorylation of MAPK were investigated using Western blotting. Emodin significantly suppressed the phosphorylation of ERK1/2 and p38 in a dose-dependent manner. However, emodin did not significantly reduce JNK phosphorylation (Fig. 5) .
Discussion
Emodin has been demonstrated to inhibit the fibrotic process in various organs, and down-regulated TGF-β1 and α-SMa in an experimental rat model of hepatic fibrosis induced by carbon tetrachloride (18) . Emodin also inhibits TGF-β1-induced tissue inhibitors of metalloproteinase (TIMP-1) by suppressing activated protein-1 (AP-1) and ERK1/2 phosphorylation in hepatic stellate cells (19) , and attenuates the pulmonary fibrosis process in bleomycin-treated mice and decreases fibroblast proliferation and collagen production (3). Emodin additionally suppresses TNF-α-induced matrix metalloproteinases by blocking the AP-1 signal, as well as by inhibiting ERK and JNK phosphorylation (20) .
Emodin plays a role in attenuating the fibrotic process in kidney disease. It reduces fibronectin expression by suppressing p38 signaling in diabetic rats and in high glucose-treated mesangial cells (4, 21) . Emodin also suppresses IL-1β-induced ECM production in mesangial cells (5) and inhibits collagen I expression in rat fibroblasts (22) . However, its mechanisms are not fully elucidated.
Here, we demonstrated for the first time that emodin inhibits fibronectin and collagen type III synthesis in NRK-49F cells (a cell line of renal interstitial fibroblasts), with or without TGF-β1 stimulation. However, emodin suppressed fibronectin and collagen type III secretion more significantly in TGF-β1-treated cells as compared to cells without TGF-β1, indicating that these inhibitory effects of emodin on ECM expression were partly dependent on TGF-β1 stimulation. TGF-β1 is the most important cytokine stimulating renal fibrosis. We have previously demonstrated that TGF-β1 activated the ERK1/2, p38 and JNK pathways in NRK-49F cells (17) . In the present study, the suppression of p38 and ERK1/2 signaling by their specific inhibitors significantly suppressed TGF-β1-induced fibronectin and collagen III secretion, but JNK inhibition did not significantly alter ECM expression, suggesting that TGF-β1 promotes ECM synthesis by activating the ERK1/2 and p38 pathways, but not the JNK pathway. Emodin has been demonstrated to attenuate MAPK activation in various types of cells (4, 19, 20) . It suppresses ERK and JNK signals in HSC5 and MDA-MB-231 cells (23) , and also attenuates TNF-α-induced JNK activation in human subconjunctival fibroblasts (24) . Emodin inhibits ERK1/2 to suppress hyaluronic acidinduced matrix metalloproteinase secretion (25) . Emodin suppresses VEGF-α-induced angiogenesis by blocking the phosphorylation of receptor-2, ERK1/2 and p38 (26) . In SH-SY5Y cells, emodin also suppresses p38 activation (27) . In IL-1-treated mesangial cells, emodin inhibits p38 and MKK3/6 phosphorylation to suppress fibronectin and collagen type IV production (5). In this study, emodin was found to suppress TGF-β1-induced ERK1/2 and p38 phosphorylation, but not JNK activation, suggesting that it may suppress fibronectin and collagen III expression by inhibiting these two signaling pathways activated by TGF-β1. Our previous study demonstrated that there was no crosstalk between the ERK1/2 and p38 pathways (17) . Therefore, emodin may suppress TGF-β1-induced ECM expression by inhibiting ERK1/2 and P38 phosphorylation in NRK-49F cells.
In conclusion, emodin suppresses fibronectin and collagen type III expression via the inhibition of the phosphorylation of ERK1/2 and P38 in TGF-β1-stimulated NRK-49F cells.
